ARROWHEAD PHARMACEUTICALS, INC.
ARWR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARWR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARWR
Arrowhead Pharmaceuticals is a clinical-stage RNAi therapeutics company advancing a pipeline of candidates for cardiometabolic, pulmonary, and other diseases, with lead programs plozasiran and zodasiran in Phase 3 trials.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$11.96B
Cash Runway
26.1 moLead Asset
Olpasiran (Phase 3)Next Catalyst
Phase3_Topline · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 56 clinical trials · 9 catalysts for ARROWHEAD PHARMACEUTICALS, INC..
Arrowhead Pharmaceuticals is a clinical-stage RNAi therapeutics company advancing a pipeline of candidates for cardiometabolic, pulmonary, and other diseases, with lead programs plozasiran and zodasiran in Phase 3 trials.
- Cash and equivalents were $54.8M as of 2026-06-30, with $1,547.2M in available-for-sale securities [sec_mda · as of 2026-08-04].
- Total revenue was $75.3M for the latest fiscal year (as of 2026-06-30), primarily from the Sarepta collaboration [sec].
- Net loss was -$194.3M for the latest fiscal year (as of 2026-06-30) [sec].
- Lead programs plozasiran (hypertriglyceridemia) and zodasiran (dyslipidemia) are in Phase 3 trials, with topline data expected from 2026 to 2028 [sec_mda · as of 2025-02-10][upcoming catalysts].
- The company has a licensing and collaboration agreement with Sarepta, which provided $325M upfront in November 2024 [sec_mda · as of 2026-08-04].
What works
- Strong balance sheet with $1.6B in total cash and securities as of 2026-06-30, expected to fund operations through multiple potential commercial launches [sec · filed 2026-01-27][sec_mda · as of 2026-08-04].
- Broad pipeline with multiple Phase 3 programs (plozasiran, zodasiran) and partnered candidates (olpasiran with Amgen, fazirsiran with Takeda) targeting large markets [sec_mda · as of 2025-02-10].
- Proprietary RNAi platform with potential to target multiple tissue types (liver, lung, CNS, muscle, adipose) and improved safety profile due to fewer metabolites [sec_mda · as of 2025-02-10].
- Revenue from collaboration agreements (e.g., Sarepta, Amgen, GSK) provides non-dilutive funding and validates platform technology [sec_mda · as of 2025-08-07].
What to weigh
- Significant net loss of -$194.3M in the latest fiscal year (as of 2026-06-30) and accumulated deficit, reflecting high R&D spending [sec].
- Cash burn rate is high; cash and equivalents dropped from $226.5M (Sep 2025) to $54.8M (Jun 2026), though offset by large securities portfolio [sec_mda · as of 2026-08-04].
- Total debt of $682.7M as of 2026-06-30, including convertible notes, adds financial leverage and potential dilution [sec].
- All pipeline candidates are in clinical or preclinical stages; no approved products or commercial revenue yet, relying on future regulatory and commercial success [sec_mda · as of 2025-08-07].
From the filings
Quoted directly from source documents.
Cash and equivalents were $54.8M as of June 30, 2026, with $1,547.2M in available-for-sale securities.
“The Company's cash, cash equivalents and restricted cash was $54.8 million as of June 30, 2026 compared to $226.5 million as of September 30, 2025. Cash invested in available-for-sale securities was $1,547.2 million as of June 30, 2026 compared to $692.8 million as of September 30, 2025.”
SEC MD&A · August 4, 2026
The company completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants with gross proceeds of $930 million.
“Completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants with gross proceeds of $930 million meaningfully strengthening the company's balance sheet and expected to provide funding through multiple potential commercial launches.”
SEC filings · January 27, 2026
Lead programs include plozasiran for hypertriglyceridemia and zodasiran for dyslipidemia, both in Phase 3.
“Hypertriglyceridemia - plozasiran (formerly ARO-APOC3); • Dyslipidemia - zodasiran (formerly ARO-ANG3);”
SEC MD&A · February 10, 2025
The company entered into a licensing and collaboration agreement with Sarepta in November 2024, receiving $325 million upfront.
“On November 25, 2024, the Company entered into a licensing and collaboration agreement with Sarepta. Upon closing, the Company received $325.0 million for the purchase of 11,926,301”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2026-09-01 · Phase3_Topline — Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in — Topline results from the Phase 3 SUMMIT program for plozasiran in hypertriglyceridemia; will determine efficacy and safety.
- 2026-09-01 · Phase3_Topline — Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in — Additional Phase 3 topline data for plozasiran, likely from a separate cohort or indication.
- 2027-08-20 · Phase3_Topline — Phase 3 Topline: Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With — Topline results for zodasiran in dyslipidemia, including homozygous familial hypercholesterolemia (HoFH).
- 2028-04-28 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the — Phase 3 topline data for another plozasiran study, likely in a broader cardiovascular population.
- 2028-07-01 · Phase3_Topline — Phase 3 Topline: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in — Long-term safety and efficacy data from the open-label extension of plozasiran.
- 2028-08-01 · Phase3_Topline — Phase 3 Topline: Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent P — Topline results for zodasiran in adolescent patients with HoFH.
- 2028-08-31 · Phase3_Topline — Phase 3 Topline: A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safet — Phase 3b topline data for a plozasiran study, likely in a specific patient subgroup.
- 2028-12-31 · Phase3_Topline — Phase 3 Topline: STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS — Topline data from a Phase 3 study on statin use in intracerebral hemorrhage patients, possibly unrelated to Arrowhead's pipeline.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 3 topline results for plozasiran and zodasiran are pending; negative data could impair pipeline value [upcoming catalysts].
- High cash burn rate — Cash and equivalents fell from $226.5M (Sep 2025) to $54.8M (Jun 2026), requiring continued capital access [sec_mda · as of 2026-08-04].
- Significant debt burden — Total debt of $682.7M as of 2026-06-30, including convertible notes, increases financial risk [sec].
- No approved products — All candidates are in clinical/preclinical stages; no commercial revenue, relying on future approvals [sec_mda · as of 2025-08-07].
What to watch
- Phase 3 topline data for plozasiran in hypertriglyceridemia expected September 2026 [upcoming catalysts].
- Phase 3 topline data for zodasiran in dyslipidemia expected August 2027 [upcoming catalysts].
- Cash runway and potential need for additional financing given high burn rate [sec_mda · as of 2026-08-04].
- Progress of partnered programs (olpasiran with Amgen, fazirsiran with Takeda) and any new collaboration deals [sec_mda · as of 2025-02-10].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ARROWHEAD PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARROWHEAD PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
26.1 months
D/E 3.54 · 0% dilution
Lead: Approved
3 candidates
9 upcoming, next in ~2d
0 buys · 8 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
436
Total value held
$7.06B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,161,519 | $1.14B |
| vanguard capital management llc | 12,064,832 | $756.5M |
| fmr llc | 7,266,652 | $455.6M |
| vanguard portfolio management llc | 7,146,136 | $448.1M |
| state street corp | 6,496,130 | $407.3M |
| geode capital management, llc | 4,278,828 | $274.5M |
| fred alger management, llc | 3,342,493 | $209.6M |
| janus henderson group plc | 2,873,980 | $180.2M |
| baker bros. advisors lp | 1,992,783 | $124.9M |
| susquehanna international group, llp | 1,836,433 | $115.1M |
Showing top 10 of 436 institutional holders of ARROWHEAD PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 12.8%
- Days to cover
- 7.3
- Shares short
- 12,939,446
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARWR short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARROWHEAD PHARMACEUTICALS, INC.?
Arrowhead Pharmaceuticals is a clinical-stage RNAi therapeutics company advancing a pipeline of candidates for cardiometabolic, pulmonary, and other diseases, with lead programs plozasiran and zodasiran in Phase 3 trials.
What is ARROWHEAD PHARMACEUTICALS, INC.'s lead drug candidate?
ARROWHEAD PHARMACEUTICALS, INC.'s most advanced tracked candidate is Olpasiran (Phase 3) for Atherosclerotic cardiovascular disease with elevated lipoprotein(a).
What is ARROWHEAD PHARMACEUTICALS, INC.'s next catalyst?
ARROWHEAD PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in" — expected September 1, 2026.
Who is the CEO of ARROWHEAD PHARMACEUTICALS, INC.?
Dr. Christopher R. Anzalone Ph.D. is the chief executive officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
Where is ARROWHEAD PHARMACEUTICALS, INC. headquartered?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is headquartered in Pasadena, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.